Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) rose 9.7% during trading on Thursday . The company traded as high as $12.81 and last traded at $12.90. Approximately 315,621 shares were traded during mid-day trading, a decline of 18% from the average daily volume of 384,213 shares. The stock had previously closed at $11.76.
Analyst Ratings Changes
A number of brokerages recently commented on BCAX. Rodman & Renshaw began coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price on the stock. Morgan Stanley initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating for the company. Finally, Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $43.75.
View Our Latest Stock Report on BCAX
Bicara Therapeutics Trading Down 2.5 %
The company has a 50-day simple moving average of $16.45.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Institutional Investors Weigh In On Bicara Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. acquired a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $177,169,000. FMR LLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $57,913,000. Braidwell LP bought a new position in shares of Bicara Therapeutics in the third quarter valued at $42,219,000. Janus Henderson Group PLC bought a new stake in Bicara Therapeutics in the 3rd quarter valued at $30,329,000. Finally, Baker BROS. Advisors LP bought a new position in shares of Bicara Therapeutics during the third quarter worth approximately $21,225,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
